Please login to the form below
RNA interference
This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.
Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for treating a hereditary form of amyloidosis, the RNA interference (RNAi)
Latest news
-
UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients
The drug is a PCSK9 inhibitor, a novel mechanism of action that uses RNA interference (RNAi) to boost the liver’s ability to remove harmful cholesterol from the blood.
-
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
-
China backs use of Roche’s Actemra for coronavirus
Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of COVID-19 RNA.
-
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate.
-
FDA clears Alnylam’s second RNAi drug for rare disease
Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari.
More from news
Approximately 1 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Silence appoints chief medical officer
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
